- Investor's Business Daily•48 minutes ago
The FDA's approval of a multiple sclerosis drug from Roche is likely to be bittersweet for Biogen, analysts said Wednesday.
- Reuters•8 hours ago
Roche's multiple sclerosis (MS) drug Ocrevus won U.S. approval, putting the potential blockbuster back on track after a brief delay and giving a lift to patients with a form of the disease that until now had no approved treatment. The drug, also known as ocrelizumab and administered via infusion, becomes the first U.S. Food and Drug Administration-approved medicine for the primary progressive form of the neurological disease (PPMS). Ocrevus, to have a list price of $65,000 annually, undercutting rival Merck's Rebif by a quarter, is also approved to treat the most common form of MS, known as relapsing-remitting multiple sclerosis (RRMS).
- Reuters•12 hours ago
The U.S. Food and Drug Administration (FDA) on Tuesday approved Roche Holding AG's multiple sclerosis (MS) drug Ocrevus, putting the potential blockbuster drug back on track after a delay caused by regulators' concerns over manufacturing issues. The infusible drug, known chemically as ocrelizumab, becomes the first U.S.-approved medicine for the primary progressive form of the neurological disease (PPMS). It is also approved to treat the most common form of the disease, known as relapsing-remitting multiple sclerosis (RRMS).
BIIB : Summary for Biogen Inc. - Yahoo Finance
Biogen Inc. (BIIB)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||268.30 x 100|
|Ask||268.51 x 400|
|Day's Range||268.20 - 273.91|
|52 Week Range||223.02 - 333.65|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||15.86|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|